The U.S. FDA on July 15 cleared Biocon Biologics Ltd.’s Kirsty (insulin aspart-xjhz) as the first and only interchangeable biosimilar product referencing Novo Nordisk A/S’ Novolog (insulin aspart), a ...

It’s time we stop creating work that holds up a mirror to what’s broken and start imagining creative solutions that inspire a ...

Market OutlineThe Global Pharmaceutical Manufacturing Market is valued at USD 576.54 Billion in 2024 and is projected to ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

WeightWatchers Completes Financial Reorganization, Strengthens Leadership, and Expands Program Innovation to Support Women Through Menopause ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters ...

The biosimilars market is estimated to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% ...

By Rishika Sadam HYDERABAD (Reuters) -Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in ...